AbbVie Extends Rinvoq U.S. Exclusivity to 2037 as AI Biotechs Move From Models to Medicines
Securing late‑decade exclusivity preserves a key immunology revenue stream as peers turn AI discoveries into first‑in‑human studies.
Overview
- On September 11, AbbVie settled with all generic challengers to extend Rinvoq’s U.S. patent protection and exclusivity to 2037, delaying generic entry by about four years.
- Rinvoq generated nearly $6 billion in 2024, a result the extended exclusivity is expected to help sustain during AbbVie’s post‑Humira transition.
- AbbVie complemented the legal win with a $195 million expansion of active pharmaceutical ingredient manufacturing announced in mid‑2025 to strengthen production capacity.
- AbCellera began Phase 1 studies in August for two AI‑designed antibodies—ABCL575 for atopic dermatitis and ABCL635 for menopausal hot flashes—and named Dr. Sarah Noonberg as chief medical officer in September, reporting 16 clinical molecules and 97 partner programs.
- Absci raised $64 million in July–August 2025 to extend its runway through mid‑2028, expanded its Almirall dermatology partnership, and announced Oracle Cloud Infrastructure and AMD collaborations that include a strategic AMD investment, with advisors added for ABS‑201, which is expected to enter clinical evaluation in early 2026.